We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Biobank Carcinoma: Storing Blood and Protein of Patients With Cancer (Biobank)

This study is currently recruiting participants.
Verified May 2016 by Maastricht Radiation Oncology
Sponsor:
ClinicalTrials.gov Identifier:
NCT01084785
First Posted: March 11, 2010
Last Update Posted: May 24, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Collaborator:
Maastricht University Medical Center
Information provided by (Responsible Party):
Maastricht Radiation Oncology
  Purpose
The purpose of this study is to determine, by means of DNA and protein analysis, the relationship between DNA and protein profiles and a number of endpoints, which are important for the patient such as overall survival and side effects.

Condition
Cancer

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Storing Blood for Analysis of DNA and Protein of Patients With Cancer in MAASTRO Clinic

Further study details as provided by Maastricht Radiation Oncology:

Biospecimen Retention:   Samples With DNA
whole blood

Estimated Enrollment: 10000
Study Start Date: January 2003
Estimated Study Completion Date: January 2025
Estimated Primary Completion Date: January 2025 (Final data collection date for primary outcome measure)
Detailed Description:
It has already been known for a long time that cancer is a genetic disorder and that the development of the illness is a very complex interaction between genetic and surrounding factors. Also the response on therapy and the development and seriousness of side effects is stipulated by this complicated collaboration of genetic and surrounding factors. Moreover it is not only the DNA that plays an important role but also the systems of control at protein level. At this moment a lot of questions remain to be answered because up till now the studies were of rather restricted statistic strength with frequently inconsistent dates and moreover retrospective. Major retrospective studies are necessary to distinguish the relationship between DNA/protein patterns and clinical relevant endpoints like prognosis and toxicity in which an as broad as possible patient group is being monitored. For this reason we want to take blood samples in MAASTRO clinic of all patients with lung cancer and to store it encrypted so that we can perform DNA and protein analyses in future and to correlate the results with survival and toxicity of the treatment.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
primary care clinic
Criteria

Inclusion Criteria:

  • cancer

Exclusion Criteria:

  • not able to comply with follow-up
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01084785


Contacts
Contact: Philippe Lambin, Prof PHD 31 (0) 088 44 55 666 philippe.lambin@maastro.nl
Contact: Dirk De Ruysscher, Prof PHD 31 (0) 088 44 55 666 dirk.deruysscher@maastro.nl

Locations
Netherlands
Maastricht Radiation Oncology Recruiting
Maastricht, Limburg, Netherlands
Contact: Dirk De Ruysscher, Prof PHD    31 (0) 88 44 55 666    dirk.deruysscher@maastro.nl   
Contact: Philippe Lambin, Prof PHD    31 (0) 88 44 55 666    philippe.lambin@maastro.nl   
Principal Investigator: Dirk De Ruysscher, Prof PHD         
Sponsors and Collaborators
Maastricht Radiation Oncology
Maastricht University Medical Center
Investigators
Principal Investigator: Dirk De Ruysscher, Prof PHD CCMO
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Maastricht Radiation Oncology
ClinicalTrials.gov Identifier: NCT01084785     History of Changes
Obsolete Identifiers: NCT00157352, NCT00157365, NCT00157391, NCT00157404, NCT00157417, NCT00157430, NCT00157443, NCT00157456, NCT00157469, NCT00157495, NCT00181337, NCT00181376, NCT00181389, NCT00181402, NCT00181415, NCT00181428, NCT00181441, NCT00181454, NCT00181467, NCT00181480, NCT00181493, NCT00181519, NCT01067872
Other Study ID Numbers: 08-06-23/01
First Submitted: March 10, 2010
First Posted: March 11, 2010
Last Update Posted: May 24, 2016
Last Verified: May 2016

Keywords provided by Maastricht Radiation Oncology:
Cancer
genomics
proteomics